Position in ALKS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,470,096
+$3,964,352 QoQ
Shares Held
199,811
+8.6% QoQ
Ownership
0.119%
of shares outstanding
% of Portfolio
0.51%
of 13F equity value
Holder Rank
#89
of 423 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Rock Springs Capital Management LP holds $59,831,908 across 7 Drug Manufacturers - Specialty & Generic names. ALKS ranks #2 (17.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
144,750 | $24,396,165 | |
| 2 | ALKS |
Alkermes plc.
This page
|
199,811 | $10,470,096 | |
| 3 | INDV |
Indivior Pharmaceuticals, Inc.
|
245,500 | $10,072,865 | |
| 4 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
499,764 | $8,975,761 | |
| 5 | TLPH |
Talphera, Inc.
|
3,589,186 | $3,696,861 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
59,000 | $1,998,920 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
22,124 | $221,240 |
All Filings in ALKS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,470,096 | 199,811 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $6,505,744 | 183,986 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,895,599 | 139,228 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,196,110 | 106,537 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||